Durable response to alectinib in a patient with advanced alk-positive non-small cell lung cancer: A case report

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. The discovery of anaplastic lymphoma kinase (ALK) gene translocations and the subsequent development of targeted therapies have transformed the prognosis for patients with advanced ALK-positive NSCLC accounting for about 3–7% of all NSCLC cases. With the introduction of targeted drugs, particularly tyrosine kinase inhibitors, treatment strategies for these patients have fundamentally changed. Alectinib, a second-generation tyrosine kinase inhibitor, has demonstrated high efficacy and improved progression-free survival as first-line therapy for ALK-positive NSCLC. This article presents a clinical case of a durable response to alectinib in a 43-year-old female patient with advanced ALK-positive lung adenocarcinoma with metastases to the lungs, pleura, and liver. First-line treatment with alectinib resulted in rapid and profound regression of tumor lesions, achieving a complete radiological response that has been maintained for 4 years. The therapy was characterized by a manageable safety profile. This observation demonstrates the potential for achieving long-term disease control and converting advanced ALK-positive NSCLC into a chronic, manageable condition with the use of alectinib as first-line therapy.

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. https://doi.org/10.1038/nature05945.

2. Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703. https://doi.org/10.1056/NEJMoa1006448.

3. Costa DB, Shaw AT, Ou SHI, Solomon BJ, Riely GJ, Ahn MJ et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881–1888. https://doi.org/10.1200/JCO.2014.59.0539.

4. Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol. 2013;20(4):e300–e306. https://doi.org/10.3747/co.20.1481.

5. Venur VA, Ahluwalia MS. Targeted therapy in brain metastases: ready for primetime? Am Soc Clin Oncol Educ Book. 2016;35:e123–e130. https://doi.org/10.14694/EDBK_100176.

6. Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinò L, Ahn M-J et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. https://doi.org/10.1056/NEJMoa1214886

7. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118–1133. https://doi.org/10.1158/2159-8290.CD-16-0596

8. Ou S-HI, Ahn JS, De Petris L, Govindan R, Yang JC-H, Hughes B et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661–668. https://doi.org/10.1200/JCO.2015.63.9443.

9. Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol. 2016;11(2):256–260. https://doi.org/10.1016/j.jtho.2015.10.024.

10. Soria JC, Tan DSW, Chiari R, Wu Y-L, Paz-Ares L, Wolf J et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–929. https://doi.org/10.1016/S0140-6736(17)30123-X.

11. Camidge DR, Kim HR, Ahn MJ, Yang JC-H, Han J-Y, Lee J-S et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2027–2039. https://doi.org/10.1056/NEJMoa1810171.

12. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim S-W et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490–2498. https://doi.org/10.1200/JCO.2016.71.5904.

13. Bazhenova LA, Gettinger SN, Langer CJ, Salgia R, Gold KA, Rosell R et al. Brigatinib in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): long-term efficacy and safety results from a phase 1/2 trial. Ann Oncol. 2017;28(Suppl. 5):V479–V480. https://doi.org/10.1093/annonc/mdx380.046.

14. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020;383(21):2018–2029. https://doi.org/10.1056/NEJMoa2027187.

15. Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–81. https://doi.org/10.1016/j.ccell.2015.05.010.

16. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74(5):1023–1028. https://doi.org/10.1007/s00280-014-2578-6.

17. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA et al. Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. J Thorac Oncol. 2019;14(11):1901–1911. https://doi.org/10.1016/j.jtho.2019.08.003.

18. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(9):829–838. https://doi.org/10.1056/NEJMoa1704795.

19. Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233–1243. https://doi.org/10.1016/j.jtho.2019.03.007.

20. Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim D-W et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056–1064. https://doi.org/10.1016/j.annonc.2020.04.478.

21. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW et al. ALEX Trial Investigators. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(9):829–838. https://doi.org/10.1016/j.annonc.2025.09.018.